News

Before Ebola virus ever struck West Africa, locals were already on the lookout for a deadly pathogen: Lassa virus. With thousands dying from Lassa every year—and the potential

The product will be renamed OBI-3424 effective immediately. OBI-3424 is a first-in-class prodrug that selectively releases a potent DNA alkylating agent in the presence of the AKR1C3 enzyme.

The applications were submitted for a single-tablet, including two-drug regimen of dolutegravir and rilpivirine for maintenance treatment of HIV-1 infection. ViiV Healthcare’s Tivicay is a dolutegravir, while Janssen

In the chronic migraine (CM) study, patients treated with fremanezumab experienced statistically significant reduction in the number of monthly headache days of at least moderate severity vs. placebo

The acquisition of Itacel will reinforce Roquette’s position as a major supplier to the pharmaceutical industry and a global leader in natural-based pharmaceutical excipients solutions. The combination of

The Range phase 3 trial evaluated the safety and efficacy of the combination of ramucirumab and docetaxel against placebo and docetaxel in a randomized, double-blinded setting. It featured 531

Under the terms of the amended 2003 collaboration and license agreement, ImmunoGen has granted Sanofi a fully-paid, exclusive license to develop, manufacture, and commercialize the following experimental compounds

Adolescents and young adults are a critical demographic for vaccination against MenB due to inherent environmental and social risk factors such as close-quartered living and sharing behaviors. “The

The continued collaboration strengthens the ongoing partnership between the two companies, focusing on the discovery of novel treatments for tropical and neurological diseases at Eisai's 14.5 acre, state-of-the-art